India Pharma and Healthcare Sector H1 FY2026 Half-Annual Review

Regulatory changes significantly impacted the pharmaceuticals and healthcare sector during the half-year from March to September 2025. The government's decision to reform the Goods and Services Tax (GST) regime for the first time since its implementation in 2017 will result in a reduction in the cost of pharmaceuticals and medical devices for end consumers. The government also expanded its price control list to include additional medications to alleviate the burden on patients with chronic conditions. Additionally, it has suggested the implementation of more comprehensive legislation to strengthen the drug price regulatory framework. The government's allocation to healthcare for the upcoming fiscal year has been increased by 11% in Budget 2025-2026. The government has also suggested the establishment of new district cancer hospitals and nursery centres to alleviate the burden on metropolitan hospitals.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for India. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in India
• Crystallise the forces both driving and restraining this sector in India
• Ascertain India’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in India.
• Build a clear picture of trends, output and consumption for specific sub-sectors